Turing Pharmaceuticals To Pull Down Price Of AIDS-Related Drug Daraprim

The outrage following the rise in the prices of Daraprim from $13.50 to $750 overnight has forced Turing Pharmaceuticals, the drug company to reduce the rates, according to BBC News.

The cause of the outrage includes the fact that Daraprim is supposed to be given to cure patients with immune system disorders and diseases, including those with HIV, AIDS and cancer.

Going by the comments in the social media, Martin Shrkeli, CEO of Turing Pharmaceuticals, has been called all kinds of names---a "morally bankrupt sociopath", a "scumbag" a "garbage monster" and "everything that is wrong with capitalism," to name some of the "tamer" comments!

He has now conceded that he would bring down the price, although he has not specified by how much.

"We've agreed to lower the price on Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit," said Shkreli.

There was a backlash from diverse sectors of the public, including the pharmaceutical industry. PhRMA, the pharmaceutical industry's main lobbying group, declared that Turing "does not represent the values of PhRMA member companies."

Shrkeli said that the decision is a reaction to the outcry. "Yes it is absolutely a reaction - there were mistakes made with respect to helping people understand why we took this action, I think that it makes sense to lower the price in response to the anger that was felt by people," he said, according to HNGN.